PEGINTERFERON LAMBDA-1A

Summary

Peginterferon Lambda-1A (CHEMBL2108723) is a phase-3 clinical-stage unknown; indicated across 7 conditions including hepatitis c virus infection and chronic hepatitis c virus infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 7 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108723
Name	PEGINTERFERON LAMBDA-1A
Type	Unknown
Max phase	3

Also known as: BMS-914143, BMS914143, PEG-IL-29, PEG-RIL-29, PEG-RLL-29, Peginterferon lambda-1a, Pegylated interferon lambda, PEGINTERFERON LAMBDA-1A

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hepatitis C virus infection	3	MONDO:0005231	EFO:0003047
chronic hepatitis C virus infection	3	MONDO:0005354	EFO:0004220
hepatitis D virus infection	3	MONDO:0005789	EFO:0007304
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
hepatitis B virus infection	2	MONDO:0005344	EFO:0004197
chronic hepatitis B virus infection	2	MONDO:0005366	EFO:0004239

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE2	7
PHASE3	6

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01447394	PHASE3	WITHDRAWN	Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C
NCT01598090	PHASE3	COMPLETED	Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
NCT01718158	PHASE3	COMPLETED	Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
NCT01754974	PHASE3	COMPLETED	Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C
NCT04967430	PHASE3	UNKNOWN	TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
NCT05070364	PHASE3	UNKNOWN	Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV
NCT01001754	PHASE2	UNKNOWN	Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
NCT01795911	PHASE2	COMPLETED	Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
NCT02765802	PHASE2	COMPLETED	A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection
NCT04331899	PHASE2	COMPLETED	Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19
NCT04343976	PHASE2	TERMINATED	Pegylated Interferon Lambda Treatment for COVID-19
NCT04354259	PHASE2	COMPLETED	Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19
NCT04388709	PHASE2	WITHDRAWN	Interferon Lambda Therapy for COVID-19

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).